Genelux publishes SCLC case report showing 16.7-month PFS with Olvi-Vec
Genelux Corporation has published a case report in peer-reviewed journal Frontiers in Oncology describing a single patient with platinum-relapsed small cell lung cancer who achieved 16.7 months of progression-free survival following intravenous administration of its oncolytic virus Olvi-Vec combined with platinum-etoposide rechallenge. That figure surpasses the 14.3-month PFS the same patient recorded during first-line platinum-based treatment.
The 58-year-old patient had progressed after four cycles of standard frontline platinum and etoposide, plus radiotherapy. After receiving a single systemically administered course of Olvi-Vec, which Genelux says was well tolerated, she was rechallenged with eight cycles of platinum and etoposide. She achieved an 84.6% reduction in target lesion size and a duration of response of 14.3 months, both exceeding her first-line outcomes. Tumour reduction after four cycles of rechallenge was also deeper than after four cycles of first-line therapy (-78.9% versus -67.8%).
Clinical context
Jason Litten, Chief Medical Officer of Genelux, was explicit about the limitations. "Although this case report reflects the outcome of a single patient and does not establish safety or efficacy or predict similar outcomes in other patients, the magnitude and duration of tumour regression are highly encouraging and align with our scientific rationale for combining Olvi-Vec with platinum-based therapy in various clinical settings," he said.
That caveat matters in the SCLC setting. The disease is characterised by a near-universal pattern of rapid relapse and acquired platinum resistance after first-line therapy; median second-line PFS in historical series is typically measured in weeks to a few months. Genelux's hypothesis is that Olvi-Vec remodels the tumour microenvironment in a way that restores sensitivity to platinum salts, though the single-patient data cannot confirm mechanism or generalisability.
The trial in question, OLVI-VEC-202-SCLC (NCT07136285), is being conducted in China by Newsoara HYK Biopharmaceuticals, Genelux's Greater China licensing partner. Enrolment is ongoing in Phase 1b dose-escalation cohorts, and additional dose-finding updates from that study are expected before year-end 2026.
Broader programme and competitive landscape
Olvi-Vec is simultaneously being evaluated in two US-based trials: the Phase 3 OnPrime/GOG-3076 study in platinum-resistant or refractory ovarian cancer, and the Phase 2 VIRO-25 trial in recurrent NSCLC in combination with platinum and an immune checkpoint inhibitor. Genelux says findings from both the SCLC and NSCLC dose-finding studies will inform a broader strategy for systemic Olvi-Vec use across solid tumour types.
The oncolytic virus space has grown steadily since the approval of talimogene laherparepvec (T-VEC) in melanoma, though systemic delivery of oncolytic agents remains a more technically challenging frontier than intratumoural injection. Several academic groups and biotechs are pursuing intravenous oncolytic platforms in lung cancer and other solid tumours, making differentiation on durability of response and tolerability profile increasingly important. Genelux's claim of consistent preclinical-to-clinical translation will need to hold across a broader patient population before the mechanism-of-sensitisation thesis can be evaluated robustly.
Investors and clinicians will focus on the forthcoming dose-escalation data from both the SCLC and NSCLC trials as the next substantive read on whether the single-patient signal observed here is reproducible at scale.